Abcam announced that it has acquired Calico Biolabs Inc. The transaction strategically expands Abcam's leading position in rabbit monoclonal antibodies, bringing a small catalogue of ready-made CAL antibodies™ for immunohistochemistry (IHC) in addition to custom development services. Calico partners with many of the leaders in diagnostics and biopharmaceuticals to create custom products for companion diagnostics. Calico's range of ready-made recombinant CAL antibodies™ for critical immuno-oncology targets will be made available at both research and commercial scale, via the Abcam global commercial network.